Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Placebo-Controlled Acebilustat (CTX 4430) in Treatment of Human Upper Extremity Lymphedema

NCT05203835 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05203835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Placebo-Controlled Acebilustat (CTX 4430) in Treatment of Human Upper Extremity Lymphedema
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2022
Completion date
December 1, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphedema of upper arm